Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2018

View Archived Issues

How resistant bacteria lock in their gains

How failing hearts try to save themselves

Efflux pumps protect against more than antibiotics

AsclepiX obtains funds to advance AXT-107

KemPharm adds drug for stimulant use disorder to pipeline

MYK-581 leads to contractile regulation with improved compliance and functional reserve in HCM model

AEG-1 as a promising new therapeutic target in Parkinson's disease

Prior experience and OX2 receptor activation is linked to social stress resilience

Blocking BigLEN-GRP171 signaling reduces opioid addiction and withdrawal in mice

Shifa Biomedical presents data on new PCSK9 inhibitor P-21

MSC-derived EVs contribute to aortic tissue repair and remodeling in aortic aneurysm via miR-147

Obesity is net positive for checkpoint blockers

National University of Singapore and collaborators patent BAD inhibitors

Leidos Biomedical Research and the University of California describe RAS GTPase inhibitors

SSAO inhibitors discovered at Sichuan Kelun-Biotech Biopharmaceutical

U.S. Rare Earth Minerals changes name to Bioxytran

Novan presents preliminary phase II results for SB-206 as treatment of molluscum contagiosum

Redx nominates oral porcupine inhibitor RXC-006 as development compound to treat IPF

Selection Bioscience presents new proteasome inhibitors

Takeda identifies extracellular calcium-sensing receptor antagonists

Five Prime initiates phase I study of first-in-class CD80 fusion protein FPT-155

Researchers present first clinical data for MK-7684

Advanced Proteome Therapeutics reports positive preclinical results with lead ADC

Data presented from a dose-escalation, phase I trial of LY-3200882

GeoVax and Virometix to collaborate on development of HPV vaccine

KEYNOTE-181 shows OS benefit with Keytruda in second-line esophageal cancer

Mission Therapeutics and AbbVie collaborate on DUB inhibitors for Alzheimer's and Parkinson's

European Commission approves Cabometyx for HCC previously treated with sorafenib

Bayer's regorafenib first to enter GBM AGILE platform trial

Interim analysis data presented for phase IIa study of GLS-4/ritonavir combination in chronic HBV

Cadent initiates phase IIa study with CAD-1883 in essential tremor

Alector initiates first-in-human study of AL-002 for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...